Completed clinical study compared the treatment effects of rabeprazole and lansoprazole depending on the genetic constitution of a enzyme in the liver in treating reflux esophagitis and the cure rate on endoscopy after treatment with rabeprazole 20 mg or lansoprazole 30 mg once daily for 4 to 8 weeks.
Study is to evaluate the pharmacokinetics (blood levels), pharmacodynamics (how the drug acts on the body), and the safety of rabeprazole sodium for the treatment of gastroesophageal reflux disease (GERD) in new borns and pre-term infants (less than 44 weeks of age).
Purpose of this study is to assess the effectiveness and safety of rabeprazole sodium, an inhibitor of gastric acid
secretion of the protein pump inhibitor (PPI) class, compared with placebo in the treatment of gastrointestinal esophageal reflux disease (GERD) in infants 1 to 11 months of age.